OKYO Pharma Limited
EMMLF · OTC
3/31/2025 | 10/1/2024 | 9/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | – | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1 | $1 | – | $3 |
| Gross Profit | -$1 | -$1 | – | -$3 |
| % Margin | – | – | – | – |
| R&D Expenses | $38 | $2,216 | – | $4 |
| G&A Expenses | $0 | $0 | – | $0 |
| SG&A Expenses | $4,140 | $792 | – | $0 |
| Sales & Mktg Exp. | $0 | $0 | – | $0 |
| Other Operating Expenses | $3,006 | -$3,006 | – | $0 |
| Operating Expenses | $7,185 | $1 | – | $4 |
| Operating Income | -$4,180 | -$3,009 | – | -$7 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $308 | -$1,089 | – | -$1 |
| Pre-Tax Income | -$3,872 | -$4,098 | – | -$8 |
| Tax Expense | -$1,846 | -$1,418 | – | $0 |
| Net Income | -$2,026 | -$2,680 | – | -$8 |
| % Margin | – | – | – | – |
| EPS | -0.04 | -0.08 | – | -0.24 |
| % Growth | 49.6% | – | – | – |
| EPS Diluted | -0.04 | -0.08 | – | -0.24 |
| Weighted Avg Shares Out | 39,488 | 33,573 | – | 33 |
| Weighted Avg Shares Out Dil | 39,488 | 33,573 | – | 33 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $0 | – | $0 |
| Interest Expense | $125 | $758 | – | $1 |
| Depreciation & Amortization | $3 | $0 | – | $0 |
| EBITDA | -$7,082 | -$2 | – | -$7 |
| % Margin | – | – | – | – |